RxDoctor Payments Data

Srijaya Bandi, MD

Family Medicine · Houston, TXNPI 1295907525

Payments from drug & device makers

$2,763in general payments, 2019–2025

Across 158 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$373
  • Optinose US, Inc.$339
  • AbbVie$335
  • Lilly USA, LLC$326
  • Amgen$261
  • AstraZeneca$252
  • plus $877 from 14 others

What the payments were for

  • Food & beverage$2,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,763 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,552
Medicare patients
121
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$85,915
JanuviaSitagliptin Phosphate32$34,650
FarxigaDapagliflozin Propanediol37$30,620
TrulicityDulaglutide15$28,719
ProliaDenosumab16$27,795
LinzessLinaclotide18$27,607
JardianceEmpagliflozin16$23,858
MounjaroTirzepatide13$22,111
Tresiba Flextouch U-100Insulin Degludec25$11,061
Atorvastatin Calcium277$1,870
Metoprolol Succinate74$1,342
Gabapentin92$1,298
Nifedipine ErNifedipine32$1,215
Rosuvastatin Calcium136$1,215
SynthroidLevothyroxine Sodium14$1,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$373$85,91568 claims
Lilly USA, LLCTrulicity, Mounjaro$326$50,83028 claims
MerckJanuvia$61$34,65032 claims
AstraZenecaFarxiga$252$30,62037 claims
AbbVieLinzess, Synthroid$335$28,80532 claims
AmgenProlia$261$27,79516 claims
Boehringer IngelheimJardiance$73$23,85816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →